|Videos|May 1, 2020

Contagion Live News Network: Coronavirus Updates for May 1, 2020

A brief summary of our daily COVID-19 coverage.

Hello and thank you for joining Contagion. I’m assistant editor Grant Gallagher, here with an update on our COVID-19 coverage on May 1, 2020.

This morning, we covered a survey out of China which found children’s depression and anxiety increase substantially in COVID-19 isolation. Investigators of the survey will continue to follow the situation to evaluate any long term trauma or ramifications on childhood development.

We also covered a study which suggested that men are more like to face fatal cases of COVID-19 than women. In a study of 43 hospitalized patients in China, men had nearly 2.5 times the death rate of women.

The reasons for the correlation between male sex and more severe disease are not clear, and it is not certain if the disparity is innately biological or lifestyle related. However, authors of the study posited that one factor could be ACE2, the protein to which the COVID-19 and SARS viruses attach. It has been shown that circulating ACE2 levels are higher in men than in women and in patients with diabetes or cardiovascular diseases

For more on these stories and other infectious disease news, visit Contagionlive.com.

For Contagion, I’m Grant Gallagher, thanks for watching.


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.